TACTIC project TACTIC is a project of the Accredited Health Research Institute, Institut de Recerca – Vall d’Hebron University Hospital (IR-HUVH), that addresses the strategic health challenges of non-communicable diseases and rare diseases in order to strengthen research based on systems medicine. The objective is to develop new perspectives for personalized and precision medicine in the fields of cancer, cardiovascular and neurological disorders, and rare diseases from childhood to adulthood. Complementary axes TACTIC is structured around two transversal axes, which are complementary to each other. The first axis is precision diagnosis and prognosis prediction, including computational biomedicine and non-invasive diagnosis. And the second, innovative therapies, with new molecular mechanisms and new therapeutic modalities. Research based on systems medicine The actions encompassed in the TACTIC program are based on the philosophy of systems medicine. This includes patient-centered medicine, primary and hospital care, translational research, computational biomedicine, and the transfer to clinical practice and impact on society. Opportunities Organizational chart Participating groups The TACTIC project is made up of five research groups, four from the Vall d’Hebron Institut de Recerca (VHIR) and one from the Vall d’Hebron Institut d’Oncologia (VHIO) Childhood Cancer and Blood Disorders Clinical Biochemistry, Drug Delivery & Therapy Cardiovascular Diseases Clinical Neuroimmunology Therapeutics and Innovations in Neuropediatrics and other paediatric rare diseases Upper Gastrointestinal and Endocrine Tumors Group Cancer Computational Biology Group Related news The Vall d’Hebron University Hospital Biobank wins the Freezer Challenge in the Biorepository Lab category The HUVH Biobank has been recognized for its sustainability and efficiency in laboratory cold storage. The 2024 revision of the McDonald criteria will allow an even earlier diagnosis of MS The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban. A new oral drug for obesity shows positive results in an international study The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors. See more "Fortalece" Program TACTIC is part of the 'Fortalece' program, an initiative of the Ministry of Science and Innovation, which incorporates a renewed model focused on simplifying administrative processes and promoting qualitative transformation. In this way, it seeks to foster cohesive development of research lines, knowledge transfer, the promotion of emerging scientific talent, and the integration of non-scientific actors or disciplinary integration, among others. 'Fortalece' is part of the state program to promote scientific-technical research and its transfer.
